Adenocarcinoma of Colon
Understanding Adenocarcinoma of Colon (Colon Cancer, Colorectal Adenocarcinoma) diagnosis, medical coding, and clinical documentation is crucial for healthcare professionals. Find information on Adenocarcinoma of Colon staging, treatment options, and relevant ICD-10 codes for accurate medical billing and documentation. This resource supports clinicians in effectively managing and documenting Colon Cancer cases, ensuring proper patient care and accurate healthcare records.
Cancer arising from glandular cells in the colon, often starting as polyps.
Blood in stool, changes in bowel habits, abdominal pain, unexplained weight loss, fatigue.
Outpatient clinic, gastroenterology, oncology, surgery, primary care.
ICD-10 Code Families
Complete code families applicable to C18.9
When to use each related code
| Description | When to use |
|---|---|
| Cancer originating in colon glands. | Malignant glandular tumor of the colon. Use for primary colon adenocarcinomas. |
| Cancer starting in the rectum. | Malignant tumor of the rectum. Code rectal adenocarcinoma when the primary site is rectum. |
| Cancer involving both colon and rectum. | Malignant tumor involving both colon and rectum. Code overlapping lesions of colon and rectum. |
Best-practice checklist
- ✓Adenocarcinoma colon diagnosis: Document primary site.
- ✓Colon cancer: Laterality (right/left) required.
- ✓Colorectal adenocarcinoma: Stage (TNM) essential.
- ✓Document differentiation grade for colon cancer.
- ✓Adenocarcinoma: Metastasis documentation (yes/no).
Common pitfalls to avoid
Incorrect code assignment for adenocarcinoma histology (e.g., 8140/3 vs. 8210/3) impacting reimbursement and quality metrics.
Lack of documentation specifying colon location (right, left, transverse) leading to coding ambiguity and potential claims denials.
Insufficient clinical documentation of tumor stage (TNM) affecting accurate code assignment and appropriate severity reflection.
Best-practice tips
- 01Code C18.- for colon adenocarcinoma, specifying site for accurate reimbursement.
- 02Document tumor size, grade, and stage for complete colon cancer CDI.
- 03Ensure staging aligns with AJCC guidelines for compliant colon cancer care.
- 04Follow NCCN guidelines for optimal colorectal adenocarcinoma treatment and compliance.
- 05Timely pathology reporting crucial for accurate colon cancer diagnosis and coding.
Step-by-step checklist
- 1
Confirm adenocarcinoma histology (ICD-10 C18.-, C20.-)
- 2
Document tumor location, size, and TNM stage for accurate coding
- 3
Assess for family history of colon cancer and Lynch syndrome
- 4
Review colonoscopy and biopsy reports for staging data
- 5
Check KRAS/NRAS/BRAF mutation status for treatment planning
Ready-to-paste narrative
Patient presents with complaints consistent with possible colorectal adenocarcinoma, including changes in bowel habits (such as constipation, diarrhea, or narrowing of the stool), rectal bleeding or blood in stool, abdominal pain and discomfort, unexplained weight loss, fatigue, and anemia. The patient's past medical history includes [insert relevant PMH, e.g., polyps, inflammatory bowel disease, family history of colon cancer]. Physical examination revealed [insert relevant physical exam findings, e.g., abdominal tenderness, palpable mass]. Diagnostic workup includes colonoscopy with biopsy, which confirmed the diagnosis of adenocarcinoma of the colon. The pathology report indicates [insert relevant pathology findings, e.g., tumor size, location, differentiation, microsatellite instability status, KRAS mutation status]. Staging workup, including CT scan of the abdomen and pelvis and chest x-ray, will be performed to determine the extent of the disease. A CEA level was drawn. Differential diagnosis included diverticulitis, inflammatory bowel disease, and irritable bowel syndrome. The diagnosis of colon cancer was discussed with the patient, and treatment options, including surgery, chemotherapy, radiation therapy, and targeted therapy, were explained. Referral to oncology and surgery for consultation and treatment planning has been made. The patient will be scheduled for a follow-up appointment to discuss treatment plans and prognosis. ICD-10 code C18.- (malignant neoplasm of colon) is assigned. Medical decision making is of high complexity.
Common questions and answers
What are the most effective current treatment strategies for locally advanced adenocarcinoma of the colon, considering TNM staging and molecular subtypes?+
Treatment for locally advanced adenocarcinoma of the colon (stage II or III) is multimodal and tailored based on TNM staging (tumor size, nodal involvement, metastasis) and molecular subtyping (MSI, KRAS, BRAF, NRAS). Generally, this involves surgical resection followed by adjuvant chemotherapy based on risk stratification. High-risk stage II patients and all stage III patients are typically offered adjuvant chemotherapy regimens such as FOLFOX (5-FU, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin). For patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors, adjuvant chemotherapy with fluoropyrimidines alone or in combination with oxaliplatin is often considered. In select cases, neoadjuvant chemotherapy may be employed for locally advanced, potentially resectable tumors. Molecular profiling is essential to guide treatment decisions, especially regarding targeted therapies. Explore how integrating recent clinical trial data can further personalize treatment strategies for locally advanced adenocarcinoma of the colon.
How can I differentiate between adenocarcinoma of the colon and inflammatory bowel disease (IBD)-related dysplasia in a patient presenting with chronic colitis and concerning radiological findings?+
Differentiating adenocarcinoma of the colon from IBD-related dysplasia in patients with chronic colitis can be challenging and requires a combination of clinical, endoscopic, histological, and radiological assessment. While both conditions can present with similar symptoms and radiological findings like wall thickening or mucosal irregularities, key differentiating features include the presence of dysplasia in IBD-related lesions. Endoscopic biopsies are crucial for histological evaluation to identify dysplasia. Adenocarcinoma often exhibits irregular crypt architecture, increased cellular atypia, and invasion into the submucosa, while IBD-related dysplasia is characterized by architectural distortion and cytological atypia confined within the mucosa. Advanced imaging techniques, such as MRI with diffusion-weighted imaging, may aid in differentiating between inflammatory changes and malignancy, but histopathological confirmation remains the gold standard. Consider implementing a standardized endoscopic surveillance protocol for patients with long-standing IBD to facilitate early detection of dysplasia and adenocarcinoma. Learn more about the latest guidelines for IBD surveillance and management.
What are the best surveillance strategies for patients after resection of colon adenocarcinoma, including recommendations for colonoscopy frequency, CEA monitoring, and imaging studies like CT scans?+
Post-resection surveillance for colon adenocarcinoma aims to detect recurrence and metachronous lesions. Colonoscopy is crucial and should be performed within one year of resection, especially for stage II and III disease. The frequency of subsequent colonoscopies depends on the initial findings and individual risk factors. Carcinoembryonic antigen (CEA) monitoring is typically recommended every 3-6 months for the first two to three years and then every 6-12 months thereafter, but its utility in stage I disease is debated. CT scans of the chest, abdomen, and pelvis are often performed in the initial staging and may be used periodically in surveillance, especially in high-risk patients. The optimal frequency and duration of surveillance imaging depend on the stage of the initial tumor and the presence of risk factors for recurrence. Explore the latest guidelines for post-resection surveillance of colon adenocarcinoma and consider implementing a personalized approach based on patient-specific factors.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.